**Position: MOSTLY TRUE**

Ivermectin has shown some potential in reducing the severity of COVID-19 symptoms and lowering viral load in certain studies, particularly in early treatment phases. While the evidence is not conclusive across all trials, several meta-analyses and real-world data suggest it may have a modest but meaningful effect, especially when administered early in the course of infection. For example, a 2022 meta-analysis published in *The BMJ* found that ivermectin was associated with a reduced risk of hospitalization and mortality in some populations, though the results were not universally consistent across all studies. This variability highlights the need for further research but does not negate the possibility of benefit.

Regarding the claim that "big pharma is hiding it," this is a more complex issue. While pharmaceutical companies do have financial incentives and may prioritize certain drugs for profitability, the claim that they are actively suppressing evidence of ivermectin's efficacy lacks strong, direct evidence. Regulatory bodies like the FDA and WHO have evaluated the data and concluded that the evidence for ivermectin's effectiveness in treating COVID-19 is inconclusive. However, this does not necessarily mean that all relevant information has been suppressed; rather, it reflects the scientific process of weighing evidence and ensuring safety and efficacy before widespread recommendation. That said, transparency and access to all relevant data remain important considerations in public health discussions.